Related Experiment Video

Updated: Jun 20, 2026

Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer
08:12

Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer

Published on: March 14, 2019

Impact of molecular markers on treatment selection in advanced colorectal cancer

Hans Prenen1, Sabine Tejpar, Eric Van Cutsem

  • 1Department of Digestive Oncology, University Hospital Gasthuisberg, Leuven, Belgium.

European Journal of Cancer (Oxford, England : 1990)
|September 25, 2009
PubMed
Abstract

No abstract available in PubMed .

More Related Videos

Ultra-Fast Amplicon-Based Next-Generation Sequencing in Non-Squamous Non-Small Cell Lung Cancer
07:59

Ultra-Fast Amplicon-Based Next-Generation Sequencing in Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

Related Experiment Videos

Last Updated: Jun 20, 2026

Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer
08:12

Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer

Published on: March 14, 2019

Ultra-Fast Amplicon-Based Next-Generation Sequencing in Non-Squamous Non-Small Cell Lung Cancer
07:59

Ultra-Fast Amplicon-Based Next-Generation Sequencing in Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

Related Concept Videos

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

Articles linked to this work by shared authors, journal, and citation graph.

Phase I safety, efficacy, and biomarker response evaluations of three oral PD-L1 inhibitors: INCB086550, INCB099280, and INCB099318.

Journal for immunotherapy of cancer·2026

Mapping the anatomical landscape of colorectal tumours: Location-specific efficacy of anti-epidermal growth factor receptor antibodies: Pooled analysis of randomised trials.

European journal of cancer (Oxford, England : 1990)·2026

Evaluation of [¹⁸F]AlF-NOTA-octreotide PET/CT in routine clinical use: a retrospective analysis in 288 neuroendocrine tumor patients.

European journal of nuclear medicine and molecular imaging·2026

Evaluating pegenzileukin (SAR444245/THOR-707) in combination with pembrolizumab or cetuximab in advanced metastatic gastrointestinal cancer: the PEGATHOR phase 2 study.

Investigational new drugs·2026

Multi-omic biomarkers of neoadjuvant treatment response in rectal cancer: A narrative review.

European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology·2026

Young onset rectal cancer (YORC): a descriptive tertiary center analysis.

European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology·2026

Towards a more proportionate EU framework for low-intervention clinical trials: Lessons from the UK and Switzerland.

European journal of cancer (Oxford, England : 1990)·2026

Recent trends in childhood, teenage and young adult cancer incidence in England (2001-2020).

European journal of cancer (Oxford, England : 1990)·2026

A randomized trial to evaluate the effect of epigallocatechin gallate (EGCG) on EBV reactivation in patients with nasopharyngeal carcinoma in remission -the TCOG T2312 study.

European journal of cancer (Oxford, England : 1990)·2026

Molecular characteristics and clinical outcomes of ERBB2-activating mutation-positive non-small cell lung cancer: A Japanese nationwide real-world cohort.

European journal of cancer (Oxford, England : 1990)·2026

Timing of first-line palliative systemic therapy in metastatic esophagogastric adenocarcinoma: A population-based analysis & target trial emulation.

European journal of cancer (Oxford, England : 1990)·2026

Liquid biopsy tumour fraction, total tumour volume, and automated whole-body CT body composition for survival stratification in metastatic cancer: A temporally validated pan-cancer cohort study.

European journal of cancer (Oxford, England : 1990)·2026

MAGEA6 Promoted Gastric Cancer Progression by Activating Mitophagy.

Molecular carcinogenesis·2026

NET-Associated Inflammatory Markers in Head and Neck Squamous Cell Carcinoma: Bioinformatic Prioritization and Exploratory Serum Assessment in Patients Undergoing Radiotherapy.

Molecular carcinogenesis·2026

Impact of PD-1 and PD-L1 inhibitors on patient-reported outcomes in esophageal squamous cell carcinoma: a systematic review of clinical trials.

Current medical research and opinion·2026

Perfusion beyond Margin in Hepatocellular Carcinoma: A Contrast-enhanced US Feature Related to Tumor Invasiveness and Prognosis.

Radiology·2026

Prognostic Value of Primary Tumor and Immune Organ Metabolic Parameters Derived from Pretreatment 18F-FDG PET/CT in Gastric Adenocarcinoma: A Retrospective Survival Analysis.

Molecular imaging and radionuclide therapy·2026

Cell-based polygenic risk scores predict clinical progression and prioritize network-based therapeutic targets in Alzheimer's disease.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us